0001246360-13-005178.txt : 20131204 0001246360-13-005178.hdr.sgml : 20131204 20131204170712 ACCESSION NUMBER: 0001246360-13-005178 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131202 FILED AS OF DATE: 20131204 DATE AS OF CHANGE: 20131204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goldberg Mark Alan CENTRAL INDEX KEY: 0001532475 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 131257962 MAIL ADDRESS: STREET 1: 128 SPRING STREET, SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form.xml PRIMARY DOCUMENT X0306 4 2013-12-02 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532475 Goldberg Mark Alan 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP,Medical&Regulatory Affairs Common Stock 2013-12-02 4 M false 7000 8.73 A 7267 D Common Stock 2013-12-03 4 S false 6587 60.49 D 680 D Common Stock 2013-12-03 4 S false 413 61.02 D 267 D Stock Option (Right to Buy) 8.73 2013-12-02 4 M false 7000 0 D 2021-09-22 Common Stock 7000 67703 D The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2012. The Stock Option granted the reporting person an option to purchase 88,703 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 09/22/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $60.02 to $60.90 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Mark Goldberg 2013-12-04